克隆氏症治療市場－全球產業規模、佔有率、趨勢、機會及預測（依藥物類型、應用、通路、地區及競爭格局分類，2021-2031年）

全球克隆氏症治療市場預計將從 2025 年的 120.4 億美元成長到 2031 年的 153.1 億美元，複合年成長率為 4.09%。

該市場涵蓋多種藥物治療方法，包括免疫調節劑、抗生素和生物製藥，旨在誘導和維持慢性發炎性疾病患者的病情緩解。市場成長的主要促進因素是已開發國家該疾病盛行率的不斷上升以及新療法的持續核准。根據克隆氏症和結腸炎基金會2024年的數據，約有100,429名20歲以下的美國人患有發炎性腸道疾病，其中克隆氏症在該年齡層的盛行率顯著高於潰瘍性大腸炎。這凸顯了持續醫療管理的日益成長的需求。

然而，市場面臨嚴峻的挑戰，因為先進生物療法的高成本往往會阻礙患者獲得治療和報銷。嚴格的監管要求以及持續治療方案帶來的沉重經濟負擔，可能會延緩有效藥物的推廣，尤其是在醫療預算有限的地區。因此，這些經濟壓力可能會限制高階治療方法的市場滲透率，迫使醫療服務提供者依賴價格較低的傳統療法。

市場促進因素

市場擴張的主要驅動力是克隆氏症在全球盛行率和發病率的持續上升。這種日益加重的疾病負擔不再局限於已開發國家，而且由於環境因素和生活方式的改變，在新興工業化地區也顯著加速成長。不斷擴大的患者群體需要長期持續的醫療管理，從而確保了對治療性介入的持續需求。歐洲克隆氏症和潰瘍性大腸炎協會聯盟 (EFCCA) 在其 2025 年世界發炎性腸道疾病日報告中指出，全球目前有超過 1,000 萬人患有發炎性腸道疾病，這凸顯了需要有效治療的患者群體規模之龐大。

同時，先進生物製藥的快速普及正在重塑市場格局。與傳統治療方法相比，先進生物製劑具有更優的療效和安全性，新藥類別也核准。醫療機構正在加速患者向下一代治療方法（例如白細胞介素抑制劑）的過渡，以實現更深層的緩解，從而推動創新療法的顯著收入成長。財務數據也印證了這個趨勢。艾伯維公司2025年1月發布的報告預測，其先進療法Skyrizi在2024年的全球淨銷售額將達到117億美元。同樣，強生公司報告稱，其成熟的生物製藥Stelara在2024年的銷售額將達到104億美元，這表明儘管面臨來自新參與企業和生物類似藥日益成長的壓力，生物製藥製劑領域的投資規模依然巨大。

市場挑戰

先進生物療法的高成本是全球克隆氏症治療市場擴張的一大障礙。儘管這些藥物療效顯著，但其定價結構給患者造成了嚴重的用藥障礙，並加重了醫療預算的負擔。保險公司通常會實施嚴格的報銷通訊協定，例如階梯療法，要求患者在核准更昂貴的治療之前，必須先嘗試其他費用較低的替代療法，且療效不佳。這種經濟負擔會降低患者的治療順從性，延誤最佳治療方案的啟動，並直接降低先進療法的獲利能力。

患者群體面臨的經濟負擔是可以量化的，而且十分沉重。據克隆氏症和結腸炎基金會稱，到2024年，超過40%的發炎性腸道疾病患者將不得不做出巨大的經濟犧牲來支付醫療費用。此外，63%服用處方藥的患者表示，他們面臨特定的經濟障礙，導致無法接受治療。無力負擔處方治療方案的費用限制了高價值生物製藥的市場滲透率，迫使市場依賴價格較低的學名藥和生物相似藥。

市場趨勢

經濟實惠的生物相似藥的加速普及正在從根本上重塑全球克隆氏症治療市場，為高價的生物製藥提供了更經濟實惠的替代方案。隨著關鍵單株抗體的專利保護期即將到期，監管機構正在加快核准生物相似藥候選藥物，從而緩解目前限制患者獲得生物療法的經濟障礙。這些低成本選擇的湧入迫使支付方調整藥品目錄結構，提高了對成本敏感地區的市場滲透率，並挑戰了品牌藥的主導地位。根據 Askera Health 於 2025 年 1 月發布的一份報告，僅在 2024 年，FDA核准了六種不同的重磅藥物Stelara的生物相似藥，這標誌著處方量將顯著轉向這些更經濟的治療方案。

同時，口服小分子療法的興起正在重新定義治療模式，它將高效性與便利的口服給藥方式結合。與需要皮下或靜脈注射的生物製藥不同，先進的Janus激酶（JAK）抑制劑和S1P受體調變器提供了非侵入性治療選擇，顯著提高了患者的生活方式柔軟性和依從性。這項轉變正在迅速發展，臨床數據顯示，這些口服療法可以達到與注射型生物製藥相當的緩解率。為了佐證這項需求，艾伯維公司於2025年1月公佈，其口服JAK抑制劑Rinvoq在2024年全年的全球淨銷售額達到60億美元，反映了這種便捷、先進的治療機制的強勁成長。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球克隆氏症治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依藥物類型（抗生素、氨基水楊酸鹽、皮質類固醇、免疫調節劑、其他）
  • 根據適應症（神經病變疼痛、纖維肌痛、慢性下背痛、關節炎疼痛、偏頭痛、術後疼痛、癌症疼痛等）
  • 按分銷管道（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美克隆氏症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲克隆氏症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區克隆氏症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲克隆氏症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲克隆氏症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球克隆氏症治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Eli Lilly and Company
• AbbVie Inc.
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Celgene Corporation
• Novartis AG
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Mylan NV
• Amgen Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Crohn's Disease Treatment Market is projected to expand from USD 12.04 Billion in 2025 to USD 15.31 Billion by 2031, reflecting a compound annual growth rate of 4.09%. This market comprises a range of pharmaceutical interventions, such as immunomodulators, antibiotics, and biologic therapies, all aimed at inducing and maintaining remission in patients suffering from this chronic inflammatory condition. Growth is primarily driven by the rising prevalence of the disease in industrialized nations and the continued approval of new therapeutic agents. Data from the Crohn's & Colitis Foundation in 2024 indicates that approximately 100,429 American youths under the age of 20 are living with Inflammatory Bowel Disease, with Crohn's disease notably more prevalent than ulcerative colitis in this demographic, highlighting the expanding need for ongoing medical management.

However, the market faces significant obstacles due to the high costs associated with advanced biologic therapies, which frequently create barriers to patient access and reimbursement. Strict regulatory requirements and the substantial financial burden of continuous treatment plans can delay the adoption of effective medications, particularly in regions with limited healthcare budgets. Consequently, these economic pressures may restrict the market penetration of premium therapeutic options, compelling healthcare providers to rely on older and less expensive alternatives.

Market Driver

The primary catalyst for market expansion is the relentlessly increasing global prevalence and incidence of Crohn's disease. This growing disease burden is no longer limited to Western nations but is visibly accelerating in newly industrializing regions, driven by shifting environmental factors and lifestyle changes. The expansion of the patient pool necessitates long-term, continuous medical management, thereby ensuring sustained demand for therapeutic interventions. Underscoring the immense scale of the population requiring effective treatment, the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) noted in their 'World IBD Day Report 2025' that there are currently over 10 million people worldwide living with inflammatory bowel diseases.

Simultaneously, the market is being reshaped by the rapid adoption of advanced biologics and the approval of novel drug classes that offer superior efficacy and safety profiles compared to legacy therapies. Healthcare providers are increasingly transitioning patients to next-generation mechanisms, such as interleukin inhibitors, to achieve deeper remission, which drives significant revenue growth for innovative formulations. Financial data substantiates this trend; according to AbbVie's January 2025 report, global net revenues for the advanced therapy Skyrizi reached $11.7 billion for the full year 2024. Similarly, Johnson & Johnson reported that the established biologic Stelara generated $10.4 billion in sales during 2024, illustrating the massive scale of investment in biologic care despite mounting pressure from newer entrants and biosimilars.

Market Challenge

The high cost of advanced biologic therapies constitutes a substantial barrier impeding the expansion of the Global Crohn's Disease Treatment Market. While these drugs offer efficacy, their pricing structures create severe accessibility issues for patients and strain healthcare budgets. Insurance providers frequently implement strict reimbursement protocols, such as step therapy, compelling patients to fail on cheaper alternatives before approving premium treatments. This financial toxicity discourages adherence and delays the initiation of optimal care, directly reducing the revenue potential for advanced therapeutic agents.

The economic strain on the patient population is quantifiable and severe. According to the Crohn's & Colitis Foundation, in 2024, more than 40% of inflammatory bowel disease patients made significant financial sacrifices to afford their healthcare. Furthermore, 63% of patients prescribed medication reported facing specific financial barriers that prevented them from obtaining their treatment. This inability to afford prescribed regimens limits the market penetration of high-value biologics and forces a market reliance on lower-cost generics or biosimilars.

Market Trends

The accelerating adoption of cost-effective biosimilars is fundamentally restructuring the Global Crohn's Disease Treatment Market by introducing affordable alternatives to high-priced legacy biologics. As patent exclusivities for major monoclonal antibodies expire, regulatory bodies are expediting the approval of biosimilar candidates, which mitigates the financial barriers currently restricting patient access to biologic therapy. This influx of lower-cost options is compelling payers to adjust formulary structures, thereby driving market penetration in cost-sensitive regions and challenging the dominance of originator drugs. According to an AscellaHealth report from January 2025, the FDA approved six distinct biosimilars for the blockbuster drug Stelara in 2024 alone, signaling a massive shift in prescription volume toward these economical therapeutic options.

Concurrently, the shift toward oral small molecule therapeutics is redefining treatment paradigms by offering potent efficacy combined with the convenience of pill-based administration. Unlike traditional biologics that require subcutaneous or intravenous delivery, advanced Janus kinase (JAK) inhibitors and S1P receptor modulators provide patients with a non-invasive option that significantly improves lifestyle flexibility and adherence. This transition is rapidly gaining momentum as clinical data demonstrates that these oral therapies can achieve remission rates comparable to injectable biologics. Highlighting this demand, AbbVie reported in January 2025 that global net revenues for the oral JAK inhibitor Rinvoq reached $6.0 billion for the full year 2024, reflecting robust growth for convenient, advanced therapeutic mechanisms.

Key Market Players

• Eli Lilly and Company
• AbbVie Inc.
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Celgene Corporation
• Novartis AG
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Mylan N.V.
• Amgen Inc

Report Scope

In this report, the Global Crohn's Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Crohn's Disease Treatment Market, By Drug Type

• Antibiotics
• Amino Salicylates
• Corticosteroids
• Immunomodulator
• Other

Crohn's Disease Treatment Market, By Application

• Neuropathic Pain
• Fibromyalgia
• Chronic Back Pain
• Arthritic Pain
• Migraine Post-Operative Pain
• Cancer Pain
• Other

Crohn's Disease Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Crohn's Disease Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Crohn's Disease Treatment Market.

Available Customizations:

Global Crohn's Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Crohn's Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulator, Other)
  • 5.2.2. By Application (Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Crohn's Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Crohn's Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Crohn's Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Crohn's Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Crohn's Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Crohn's Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Crohn's Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Crohn's Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Crohn's Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Crohn's Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Crohn's Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Crohn's Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Crohn's Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Crohn's Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Crohn's Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Crohn's Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Crohn's Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Crohn's Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Crohn's Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Crohn's Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America Crohn's Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Crohn's Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Crohn's Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Crohn's Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Crohn's Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Eli Lilly and Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AbbVie Inc.
• 15.3. AstraZeneca plc
• 15.4. Boehringer Ingelheim GmbH
• 15.5. Celgene Corporation
• 15.6. Novartis AG
• 15.7. Sanofi SA
• 15.8. Takeda Pharmaceutical Company Limited
• 15.9. Mylan N.V.
• 15.10. Amgen Inc

16. Strategic Recommendations

17. About Us & Disclaimer